| Literature DB >> 21403903 |
Marjaneh Fatemi1, Grégoire Le Gal, Jean-Jacques Blanc, Jacques Mansourati, Yves Etienne.
Abstract
Cardiac resynchronization therapy (CRT) has been demonstrated to improve symptoms and survival in patients with left ventricular (LV) systolic dysfunction and dyssynchrony. To achieve this goal, the LV lead should be positioned in a region of delayed contraction. We hypothesized that pacing at the site of late electrical activation was also associated with long-term response to CRT. We conducted a retrospective study on 72 CRT patients. For each patient, we determined the electrical delay (ED) from the onset of QRS to the epicardial EGM and the ratio of ED to QRS duration (ED/QRS duration). After a followup of 30 ± 20 months, 47 patients responded to CRT. Responders had a significantly longer ED and greater ratio of ED/QRS duration than nonresponders. An ED/QRS duration ≥0.38 predicted a response to CRT with 89% specificity and 53% sensitivity.Entities:
Year: 2011 PMID: 21403903 PMCID: PMC3043300 DOI: 10.4061/2011/956062
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Figure 1Recording of the epicardial EGM at the tip of the LV lead. a: QRS duration, b: electrical delay.
Comparison of clinical characteristics in responders and nonresponders.
| Responders | Nonresponders | ||
|---|---|---|---|
| Age (years) | 70 ± 7 | 72 ± 8 | .36 |
| NIDCM (%) | 72 | 60 | .29 |
| SR at implant (%) | 89 | 92 | .72 |
| NYHA class | 3.3 ± 0.5 | 3.1 ± 0.7 | .37 |
| NYHA class | |||
| Class III (%) | 69 | 73 | .71 |
| Class IV (%) | 31 | 27 | |
| Baseline treatment | |||
| Beta-blocker (%) | 67 | 65 | .91 |
| ACE inhibitor (%) | 73 | 81 | .48 |
| ARA (%) | 22 | 12 | .35 |
| Diuretics (%) | 98 | 92 | .55 |
| Spironolactone | 38 | 42 | .71 |
| Digoxin (%) | 27 | 31 | .71 |
| Statin (%) | 40 | 42 | .85 |
| Treatment at followup | |||
| Beta-blocker (%) | 80 | 65 | .17 |
| ACE inhibitor (%) | 78 | 65 | .26 |
| ARA (%) | 29 | 23 | .59 |
| Diuretics (%) | 98 | 100 | 1 |
| Spironolactone | 27 | 42 | .18 |
| Digoxin (%) | 24 | 42 | .12 |
| Statin (%) | 49 | 46 | .82 |
| Change of treatment during followup (%) | 89 | 89 | 1 |
| 6-minute walked distance (m) | 354 ± 126 | 348 ± 119 | .88 |
| Follow-up duration (months) | 32.1 ± 20.9 | 27.3 ± 19.1 | .35 |
| Δ NYHA class | −1.6 ± 0.7 | −0.2 ± 0.9 | <.001 |
Abbreviations used: SR: sinus rhythm, NIDCM: nonischemic dilated cardiomyopathy, NYHA class: New York Heart Association functional class, ACE inhibitors: angiotensin converting enzyme inhibitors, ARA: angiotensin receptor antagonist, Δ NYHA: difference of NYHA class between followup and baseline.
Comparison of echocardiography and electrical parameters in responders and nonresponders.
| Responders | Nonresponders | ||
|---|---|---|---|
| Spontaneous QRS duration (ms) | 177 ± 31 | 180 ± 26 | .69 |
| ED (ms) | 139 ± 35 | 119 ± 37 | .03 |
| Ratio of ED/QRS duration | 0.78 ± 0.15 | 0.68 ± 0.19 | .02 |
| LVEF (%) | 25 ± 8 | 20 ± 7 | .01 |
| Baseline LVESV (mL) | 182 ± 57 | 240 ± 63 | <.001 |
| Baseline LVEDV (mL) | 269 ± 62 | 319 ± 75 | .005 |
| Δ LVEF (%) | +19.5 ± 11.9 | −0.8 ± 7.7 | <.001 |
| Δ LVESV (mL) | −55 ± 72 | +5 ± 62 | .002 |
| Δ LVESV (mL) | −68 ± 66 | +5 ± 58 | .001 |
Abbreviations: ED: electrical delay, LVEF: left ventricular ejection fraction, Δ LVEF: difference of LVEF between followup and baseline, LVESV: left ventricular end-systolic volume, LVEDV: left ventricular end-diastolic volume, Δ LVESV: difference of LVESV between followup and baseline, Δ LVESD: difference of LVESV between followup and baseline.
Figure 2Correlation between ED and Δ LVEF (a) and Δ NYHA class (b). Abbreviations: ED: electrical delay, Δ LVEF: difference of LVEF between long-term followup and baseline, Δ NYHA: difference of NYHA class between long-term followup and baseline.
Figure 3Correlation between ratio of ED/QRS duration and Δ LVEF (a) and Δ NYHA class (b). Abbreviations: ED: electrical delay, Δ LVEF: change in LVEF from baseline to long-term followup, Δ NYHA: change in NYHA class from baseline to long-term followup.
Multivariate predictors of response to CRT.
| OR | (95% CI) | ||
|---|---|---|---|
| SR at implant | 1.3 | 0.2–10.1 | .80 |
| NIDCM | 1.3 | 0.4–4.4 | .69 |
| LVEF | 1.08 | 1.002–1.17 | .045 |
| Ratio of ED/QRS duration ≥0.83 | 6.8 | 1.7–27.5 | .007 |
Abbreviations used: OR: odds ratio, CI: confidence interval, SR: sinus rhythm, NIDCM: nonischemic dilated cardiomyopathy, LVEF: left ventricular ejection fraction, ED: electrical delay.
Comparison of the value of ED in patients with ischemic and nonischemic cardiomyopathy.
| IDCM | NIDCM | |||
|---|---|---|---|---|
| ED versus Δ LVEF | +0.39 | .06 | +0.20 | .17 |
| ED versus Δ NYHA | −0.44 | .03 | −0.26 | .07 |
| Ratio of ED/QRS duration versus Δ LVEF | +0.37 | .08 | +0.08 | .57 |
| Ratio of ED/QRS duration versus Δ NYHA | −0.41 | .05 | −0.23 | .11 |
Abbreviations: IDCM: ischemic dilated cardiomyopathy, NIDCM: nonischemic dilated cardiomyopathy, ED: electrical delay, Δ LVEF: difference of LVEF between follow-up and baseline, Δ NYHA: difference of NYHA between follow-up and baseline, r: correlation coefficient determined by regression analysis, P: P value.
Figure 4Distribution of ED (a) and ratios of ED/QRS duration (b) as a function of LV lead position in the LAO view. Abbreviations: ED: electrical delay, LAO: left anterior oblique.